Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC

Autor: Martin P. Barr, Anne-Marie Baird, Sophia Halliday, Petra Martin, Emma H. Allott, James Phelan, Greg Korpanty, Linda Coate, Cathal O’Brien, Steven G. Gray, Jane S. Y. Sui, Brian Hayes, Sinead Cuffe, Stephen P. Finn

Publikováno v: Diagnostics, Vol 12, Iss 10, p 2360 (2022)

The liquid biopsy has the potential to improve patient care in the diagnostic and therapeutic setting in non-small cell lung cancer (NSCLC). Consented patients with epidermal growth factor receptor (EGFR) positive disease (n = 21) were stratified int

Externí odkaz: https://doaj.org/article/57653e20063243da8a3fe1ac5629d75d

Frequency of breast cancer subtypes among African American women in the AMBER consortium

Autor: Emma H. Allott, Joseph Geradts, Stephanie M. Cohen, Thaer Khoury, Gary R. Zirpoli, Wiam Bshara, Warren Davis, Angela Omilian, Priya Nair, Rochelle P. Ondracek, Ting-Yuan David Cheng, C. Ryan Miller, Helena Hwang, Leigh B. Thorne, Siobhan O’Connor, Traci N. Bethea, Mary E. Bell, Zhiyuan Hu, Yan Li, Erin L. Kirk, Xuezheng Sun, Edward A. Ruiz-Narvaez, Charles M. Perou, Julie R. Palmer, Andrew F. Olshan, Christine B. Ambrosone, Melissa A. Troester

Publikováno v: Breast Cancer Research, Vol 20, Iss 1, Pp 1-9 (2018)

Abstract Background Breast cancer subtype can be classified using standard clinical markers (estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)), supplemented with additional markers. However, autom

Externí odkaz: https://doaj.org/article/80d9c8b315bf4e3fbb41c7845035630d

Statins and prostate cancer—hype or hope? The epidemiological perspective

Autor: Emma L. Craig, Konrad H. Stopsack, Emma Evergren, Linda Z. Penn, Stephen J. Freedland, Robert J. Hamilton, Emma H. Allott

Publikováno v: Craig, E L, Stopsack, K H, Evergren, E, Penn, L Z, Freedland, S J, Hamilton, R J & Allott, E H 2022, ' Statins and prostate cancer—hype or hope? The epidemiological perspective ', Prostate cancer and prostatic diseases . https://doi.org/10.1038/s41391-022-00554-1

Background Men using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and prospective cohort studies. Statin use has also been associated with lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fffc7426190b85312616ca1ea8708723
https://doi.org/10.1038/s41391-022-00554-1

Supplementary Table S1 from Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial

Autor: Stephen J. Freedland, Gerald L. Andriole, Ramiro Castro-Santamaria, Daniel M. Moreira, Adriana C. Vidal, Lauren E. Howard, Emma H. Allott

Supplementary Table S1. Demographic characteristics of REDUCE participants in the analytic cohort, and in the group excluded due to missing lipid levels.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd7fea84895607fbbbd42e24ebdbaad3
https://doi.org/10.1158/1940-6207.22532519.v1

Table S3 from Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer

Autor: Lorelei A. Mucci, Stephen P. Finn, Christopher J. Sweeney, Edward Giovannucci, Meir J. Stampfer, Massimo Loda, Elizabeth A. Platz, Philip W. Kantoff, Tamara L. Lotan, Stephen J. Freedland, Jennifer R. Rider, Mary K. Downer, Travis A. Gerke, Thomas U. Ahearn, Kathryn M. Wilson, Sarah C. Markt, Amparo G. Gonzalez-Feliciano, Konrad H. Stopsack, Ericka M. Ebot, Emma H. Allott

Hazard ratios and 95% confidence intervals of the association between statin use and risk of prostate cancer subgroups classified by ERG and PTEN status

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e5e4a18e33f18b4bd2cef4604106234
https://doi.org/10.1158/1078-0432.22477604